GenEdit develops novel engineering and delivery approaches to better enable CRISPR-Cas9 for human therapeutics. CRISPR-Cas9 is a revolutionary technology, discovered at UC Berkeley in 2012, that enables precisely targeted genome editing. CRISPR-based therapeutics have the potential to cure hundreds of genetic diseases. GenEdit is actively working on how to safely and efficiently deliver CRISPR-Cas9 treatments into the human body. Our proprietary, non-viral delivery system can potentially form the leading platform for safe and efficient CRISPR-based drug delivery.